Core Insights - Dentsply International (XRAY) is currently viewed as a better value investment compared to Merit Medical (MMSI) based on various financial metrics and analyst outlooks [1][3][7] Valuation Metrics - XRAY has a forward P/E ratio of 8.73, significantly lower than MMSI's forward P/E of 28.03, indicating XRAY may be undervalued [5] - The PEG ratio for XRAY is 1.18, while MMSI's PEG ratio is 2.73, suggesting XRAY has a more favorable earnings growth outlook relative to its price [5] - XRAY's P/B ratio stands at 1.64, compared to MMSI's P/B of 3.89, further indicating XRAY's superior valuation [6] Analyst Ratings - XRAY holds a Zacks Rank of 2 (Buy), while MMSI has a Zacks Rank of 3 (Hold), reflecting a more positive earnings estimate revision for XRAY [3][7] - Based on the combination of earnings outlook and valuation metrics, XRAY is positioned as the superior value option in the medical-dental supplies sector [7]

Core Viewpoint - Investors in the Medical - Dental Supplies sector should consider Dentsply International (XRAY) as a potentially undervalued stock compared to Merit Medical (MMSI) [1] Group 1: Company Rankings and Valuation Metrics - Dentsply International has a Zacks Rank of 2 (Buy), while Merit Medical has a Zacks Rank of 4 (Sell), indicating a more favorable earnings estimate revision trend for XRAY [3] - XRAY has a forward P/E ratio of 8.25, significantly lower than MMSI's forward P/E of 27.73, suggesting XRAY may be undervalued [5] - The PEG ratio for XRAY is 1.12, while MMSI's PEG ratio is 2.70, further indicating XRAY's better valuation relative to expected earnings growth [5] Group 2: Additional Valuation Metrics - XRAY's P/B ratio is 1.55, compared to MMSI's P/B of 3.85, highlighting XRAY's more favorable market value relative to its book value [6] - These metrics contribute to XRAY's Value grade of A and MMSI's Value grade of D, reinforcing the view that XRAY is the better investment option for value investors [6]

Core Viewpoint - Dentsply Sirona (XRAY) is identified as a strong value stock, currently holding a Zacks Rank of 2 (Buy) and an A rating in the Value category, indicating potential for profitability due to its undervaluation compared to industry averages [4][9]. Valuation Metrics - XRAY has a Forward P/E ratio of 8.2, significantly lower than the industry average of 16.70, with a 52-week range of 6.77 to 12.54 [4]. - The PEG ratio for XRAY stands at 1.11, which is below the industry average of 1.79, with a 52-week range of 0.84 to 1.91 [5]. - The P/B ratio for XRAY is 1.59, compared to the industry average of 4.34, with a 52-week range of 1.24 to 2.16 [6]. - XRAY's P/S ratio is 0.84, which is lower than the industry average of 1.26, indicating a favorable valuation based on sales [7]. - The P/CF ratio for XRAY is 15.45, compared to the industry average of 17.01, with a 52-week range of 7.83 to 19.05 [8]. Investment Outlook - The combination of these valuation metrics suggests that Dentsply Sirona is likely undervalued, making it an attractive option for value investors seeking strong earnings outlooks [9].

Company Overview - Dentsply Sirona Inc. (XRAY) is experiencing significant attention from investors due to high implied volatility in its options market, particularly the Jul 18, 2025 $7.50 Call option [1] - The company currently holds a Zacks Rank 3 (Hold) in the Medical - Dental Supplies industry, which is positioned in the top 22% of the Zacks Industry Rank [3] Analyst Insights - Over the past 30 days, two analysts have raised their earnings estimates for Dentsply Sirona for the current quarter, resulting in an increase in the Zacks Consensus Estimate from 49 cents per share to 50 cents [3] Market Expectations - The high implied volatility suggests that options traders are anticipating a significant price movement for Dentsply Sirona shares, potentially indicating an upcoming event that could lead to a major rally or sell-off [2][4] - Options traders often seek to capitalize on high implied volatility by selling premium, aiming for the underlying stock to not move as much as expected by expiration [4]

Core Viewpoint - DENTSPLY SIRONA (XRAY) is positioned for growth through its new digital-implant workflow and ongoing research and development focus, although it faces forex headwinds and demand softness in Europe [1][3]. Company Overview - DENTSPLY SIRONA has a market capitalization of $3.23 billion and is a global leader in dental consumables, laboratory products, specialty products, and medical devices, with an expected earnings improvement of 7.4% over the next five years [2]. Growth Factors - The introduction of the Azento solution is transforming digital implant workflows, enhancing planning, purchasing, and delivery for single-tooth replacements, now available in Canada and Europe, positioning the company in the $20 billion global tooth-replacement market [3][6]. - Demand for 3D imaging and treatment centers is increasing due to technological upgrades and supply-chain recovery, while the company's expansion in clear aligners further enhances its digital dentistry ecosystem [3]. - DENTSPLY SIRONA's growth strategy is heavily reliant on product innovation, supported by increased R&D spending, which reached $36 million in Q1 2025, aimed at delivering sustainable innovation [4][7]. Financial Performance - In Q1 2025, DENTSPLY SIRONA reported an adjusted operating profit of $72 million, a 46.9% increase from the previous year, with an adjusted operating margin expanding by 305 basis points to 8.2% [8]. - The Zacks Consensus Estimate for 2025 revenues is $3.65 billion, reflecting a 3.7% decrease from 2024, while the consensus for adjusted earnings per share is $1.90, indicating a 13.8% year-over-year improvement [10]. Challenges - There is a noted softness in demand for CAD/CAM products in Europe, particularly in Germany, which is impacting sales and is expected to continue affecting the company in the upcoming quarters [9].

Core Viewpoint - Dentsply Sirona Inc. has announced a $550 million offering of 8.375% Junior Subordinated Notes due 2055, expected to close on June 12, 2025, subject to customary conditions [1] Group 1: Offering Details - The notes will have a fixed interest rate of 8.375% until September 12, 2030, after which the rate will reset based on the five-year U.S. Treasury rate plus a spread of 4.379%, with a minimum rate of 8.375% [2] - The net proceeds from the offering are expected to be approximately $544.5 million, which will be used for general corporate purposes, including repaying existing short-term indebtedness [3] Group 2: Management and Regulatory Information - Goldman Sachs & Co. LLC is the sole book-running manager for the offering, with several co-managers involved [4] - The offering is being made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission [4][5] Group 3: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, with a strong portfolio of brands and a commitment to advancing patient care [8][9]

Core Insights - The article suggests that investors should avoid shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) based on a long-term analysis of the company's performance and market sentiment [1] Company Analysis - The author has been tracking DENTSPLY SIRONA Inc. for nearly 7.5 years, indicating a sustained negative outlook on the stock [1] - The author utilizes a software tool that measures market optimism and pessimism, aiming to identify discrepancies between market perceptions and actual outcomes [1] Investment Strategy - The investment approach focuses on companies that are likely to surprise the market positively in the near future, suggesting a strategy that capitalizes on market inefficiencies [1]

Core Viewpoint - Dentsply International (XRAY) is experiencing solid improvements in earnings estimates, which may lead to continued short-term price momentum for the stock [1][2]. Estimate Revisions - The rising trend in estimate revisions reflects growing analyst optimism regarding Dentsply's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Dentsply is projected to earn $0.50 per share, representing a year-over-year increase of +2.04%. Over the last 30 days, eight estimates have been revised upward, resulting in a 9.41% increase in the Zacks Consensus Estimate [6]. - For the full year, the expected earnings per share is $1.89, indicating a +13.17% change from the previous year. Nine estimates have moved higher in the past month, contributing to a 5.06% increase in the consensus estimate [7][8]. Zacks Rank - Dentsply has achieved a Zacks Rank of 2 (Buy), indicating favorable estimate revisions. Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9]. - The Zacks Rank system has a strong track record, with Zacks 1 Ranked stocks generating an average annual return of +25% since 2008 [3]. Stock Performance - Dentsply shares have increased by 17.2% over the past four weeks, suggesting that investors are responding positively to the company's impressive estimate revisions [10].

Core Viewpoint - Investors in the Medical - Dental Supplies sector should consider Dentsply International (XRAY) and The Cooper Companies (COO) for potential value opportunities, with XRAY currently showing stronger metrics and analyst outlook [1][3]. Valuation Metrics - Dentsply International (XRAY) has a forward P/E ratio of 8.64, while The Cooper Companies (COO) has a forward P/E of 20.09, indicating XRAY may be undervalued [5]. - The PEG ratio for XRAY is 1.17, compared to COO's PEG ratio of 2.02, suggesting XRAY has a more favorable growth outlook relative to its valuation [5]. - XRAY's P/B ratio is 1.62, while COO's P/B ratio is 1.96, further supporting XRAY's stronger valuation metrics [6]. Analyst Outlook - XRAY holds a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to COO, which has a Zacks Rank of 3 (Hold) [3][7]. - The improving analyst outlook for XRAY suggests it is a more attractive option for value investors at this time [3][7].

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...